
About Fermenta Biotech Limited
Data last updated:
Fermenta Biotech Limited is a public limited company based in Thane, Maharashtra, India, a subsidiary of Dvk Investments Private Limited. It operates in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 01 May 1951 and has been in existence for over 75 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L99999MH1951PLC008485. Its GSTIN is 27AAACD0525E1Z9 (Maharashtra). The company holds 14 GST registrations, of which 13 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 506414 and NSE: FERMENTA.
The company has an authorised share capital of ₹31.83 Cr and a paid-up capital of ₹14.72 Cr. It was formerly known as International Franchises Private Limited and International Franchises Limited. It is led by directors including Prashant Prabhakar Nagre (Managing Director) and Anupama Datla Desai (Whole-Time Director).
Its last annual general meeting (AGM) was held on 12 August 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at A – 1501 Thane One Dil Complex Ghodbunder Road Majiwade Thane (West) 400 610 Maharash, Tra India, Maharashtra, India – 400610.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹525.43 Cr, a growth of 11.9% compared to the previous year. For the same year it recorded a net profit of ₹62.91 Cr (net margin 12%) and EBITDA of ₹100.96 Cr (EBITDA margin 19.2%). The net worth stands at ₹406.22 Cr (up 12% YoY). Total assets are valued at ₹541.41 Cr (up 8.7% YoY).
The company has about 327 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.
As per MCA filings, the company has open charges of ₹294.16 Cr and satisfied charges of ₹351.46 Cr on record. Court records list 28 cases involving the company, including 15 filed by the company and 13 filed against it; 2 cases are pending.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website fermentabiotech.com.
Company details
Name history
Fermenta Biotech has undergone 3 name changes throughout its history. The company was previously known as International Franchises Private Limited, International Franchises Limited, and Dil Limited. The current legal name is Fermenta Biotech Limited.
| Company Name | Status |
|---|---|
| Fermenta Biotech Limited | Current |
| International Franchises Private Limited | Previous |
| International Franchises Limited | Previous |
| Dil Limited | Previous |
Contact details
Fermenta Biotech Limited's registered office is in Thane, Maharashtra. Its website is fermentabiotech.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressA – 1501 Thane One Dil Complex Ghodbunder Road Majiwade Thane (West) 400 610 Maharash, Tra India, Maharashtra, India – 400610
- IndustryPharma, API Manufacturers
To see the full contact details of Fermenta Biotech Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Financials of Fermenta Biotech Limited
FY 2025-26 filings availableFermenta Biotech Limited reported revenue of ₹525.43 Cr (up 11.9% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 525 | 469 | 336 | 350 | 399 | 377 | 292 |
| Revenue growth | +11.9% | +39.9% | -4.1% | -12.2% | +5.6% | +29.3% | - |
| EBITDA | 101 | 111 | 20.47 | (10.28) | 62.36 | 82.69 | 66.19 |
| EBITDA margin | +19.2% | +23.5% | +6.1% | -2.9% | +15.7% | +21.9% | +22.7% |
| Profit before tax | 95.86 | 83.22 | (9.87) | (51.30) | 26.96 | 51.63 | 43.42 |
| Net profit | 62.91 | 81.06 | (16.63) | (23.95) | 15.47 | 45.64 | 57.78 |
| Net profit margin | +12.0% | +17.3% | -5.0% | -6.8% | +3.9% | +12.1% | +19.8% |
| EPS (₹) | 25.03 | 26.35 | (7.99) | (17.70) | 5.35 | 15.77 | 20.63 |
| Balance sheet | |||||||
| Total assets | 541 | 498 | 465 | 562 | 622 | 598 | 539 |
| Net worth | 406 | 363 | 289 | 315 | 372 | 361 | 309 |
| Total debt | 113 | 115 | 139 | 220 | 239 | 232 | 224 |
| Cash & bank | 41.34 | 71.70 | 59.83 | 58.33 | 33.61 | 44.53 | 33.11 |
| Net working capital | 282 | 219 | 159 | 175 | 229 | 220 | 209 |
| Cash flow | |||||||
| Cash from operations | 92.83 | 40.90 | 105 | 116 | 43.44 | 62.60 | 34.46 |
| Cash from investing | (43.00) | (0.16) | (15.50) | (55.36) | (26.04) | (40.94) | (43.66) |
| Cash from financing | (42.29) | (50.87) | (90.85) | (41.38) | (21.58) | (1.14) | (47.45) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 122 | 122 | 137 | 130 | 136 | 140 | 156 | 95.03 |
| Revenue growth (YoY) | -10.6% | -13.1% | -12.2% | +37.0% | +74.4% | - | - | - |
| Other income | 4.37 | 14.14 | 3.12 | 5.43 | 8.77 | 3.89 | 2.23 | 2.88 |
| EBITDA | 18.05 | 20.00 | 22.77 | 26.63 | 28.23 | 36.95 | 53.27 | 18.78 |
| EBITDA margin | +14.8% | +16.5% | +16.6% | +20.5% | +20.7% | +26.4% | +34.0% | +19.8% |
| Depreciation | 5.20 | 5.11 | 5.37 | 5.41 | 5.81 | 5.86 | 6.08 | 6.15 |
| Interest | 2.54 | 2.82 | 3.03 | 2.58 | 3.11 | 2.99 | 4.08 | 3.69 |
| Profit before tax | 14.68 | 26.21 | 17.49 | 24.07 | 28.08 | 31.99 | 45.34 | 11.82 |
| Tax | 5.16 | 7.61 | 5.46 | 6.06 | 6.48 | (1.34) | 7.45 | 0.70 |
| Net profit | 9.52 | 18.60 | 12.03 | 18.01 | 21.60 | 33.33 | 37.89 | 11.12 |
| EPS (₹) | 3.34 | 6.61 | 4.34 | 6.15 | 7.47 | 11.79 | 12.71 | 3.94 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 450 | 431 | 307 | 329 | 388 | 373 | 299 |
| Revenue growth | +4.6% | +40.2% | -6.6% | -15.2% | +4.1% | +24.6% | - |
| EBITDA | 91.67 | 101 | 28.33 | (20.61) | 76.82 | 94.73 | 70.45 |
| EBITDA margin | +20.4% | +23.4% | +9.2% | -6.3% | +19.8% | +25.4% | +23.5% |
| Profit before tax | 89.22 | 74.42 | (4.62) | (57.99) | 42.57 | 63.22 | 47.55 |
| Net profit | 55.21 | 71.71 | (7.75) | 3.07 | 30.26 | 52.09 | 61.77 |
| Net profit margin | +12.3% | +16.7% | -2.5% | +0.9% | +7.8% | +14.0% | +20.6% |
| EPS (₹) | 22.42 | 23.18 | (6.49) | (19.75) | 10.48 | 18.01 | 22.07 |
| Balance sheet | |||||||
| Total assets | 563 | 519 | 494 | 585 | 649 | 610 | 544 |
| Net worth | 423 | 380 | 314 | 336 | 396 | 370 | 313 |
| Total debt | 113 | 115 | 139 | 219 | 241 | 234 | 226 |
| Cash & bank | 18.02 | 61.95 | 56.64 | 55.11 | 30.75 | 41.30 | 32.37 |
| Net working capital | 270 | 218 | 168 | 172 | 251 | 235 | 216 |
| Cash flow | |||||||
| Cash from operations | 82.63 | 33.83 | 105 | 124 | 50.41 | 62.96 | 29.83 |
| Cash from investing | (46.00) | 0.41 | (15.15) | (63.47) | (32.46) | (43.61) | (39.19) |
| Cash from financing | (42.15) | (50.91) | (90.86) | (41.25) | (21.76) | (1.32) | (47.63) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 112 | 110 | 114 | 107 | 119 | 122 | 146 | 89.54 |
| Revenue growth (YoY) | -6.0% | -10.0% | -21.9% | +19.6% | +63.7% | - | - | - |
| Other income | 4.90 | 15.17 | 3.43 | 5.53 | 8.84 | 3.88 | 2.22 | 2.95 |
| Total expenses | 88.86 | 88.04 | 92.88 | 84.15 | 96.49 | 89.36 | 96.12 | 74.05 |
| EBITDA | 22.98 | 21.84 | 21.36 | 22.97 | 22.53 | 32.68 | 50.13 | 15.49 |
| EBITDA margin | +20.5% | +19.9% | +18.7% | +21.4% | +18.9% | +26.8% | +34.3% | +17.3% |
| Depreciation | 5.19 | 5.08 | 5.17 | 5.13 | 5.55 | 5.60 | 5.82 | 5.89 |
| Interest | 2.54 | 2.77 | 3.03 | 2.59 | 3.11 | 2.99 | 4.09 | 3.69 |
| Profit before tax | 20.15 | 29.16 | 16.59 | 20.78 | 22.71 | 27.97 | 42.44 | 8.86 |
| Tax | 5.16 | 7.58 | 4.83 | 6.06 | 6.48 | (1.34) | 7.45 | 0.70 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 122 | 122 | 137 | 130 | 136 | 140 | 156 | 95.03 |
| Revenue growth (YoY) | -10.6% | -13.1% | -12.2% | +37.0% | +74.4% | - | - | - |
| Other income | 4.37 | 14.14 | 3.12 | 5.43 | 8.77 | 3.89 | 2.23 | 2.88 |
| EBITDA | 18.05 | 20.00 | 22.77 | 26.63 | 28.23 | 36.95 | 53.27 | 18.78 |
| EBITDA margin | +14.8% | +16.5% | +16.6% | +20.5% | +20.7% | +26.4% | +34.0% | +19.8% |
| Depreciation | 5.20 | 5.11 | 5.37 | 5.41 | 5.81 | 5.86 | 6.08 | 6.15 |
| Interest | 2.54 | 2.82 | 3.03 | 2.58 | 3.11 | 2.99 | 4.08 | 3.69 |
| Profit before tax | 14.68 | 26.21 | 17.49 | 24.07 | 28.08 | 31.99 | 45.34 | 11.82 |
| Tax | 5.16 | 7.61 | 5.46 | 6.06 | 6.48 | (1.34) | 7.45 | 0.70 |
| Net profit | 9.52 | 18.60 | 12.03 | 18.01 | 21.60 | 33.33 | 37.89 | 11.12 |
| EPS (₹) | 3.34 | 6.61 | 4.34 | 6.15 | 7.47 | 11.79 | 12.71 | 3.94 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 525 | 469 | 336 | 350 | 399 | 377 | 292 |
| Revenue growth | +11.9% | +39.9% | -4.1% | -12.2% | +5.6% | +29.3% | - |
| Other income | 29.26 | 11.82 | 11.81 | 8.60 | 8.14 | 8.25 | 12.32 |
| Total expenses | 424 | 359 | 315 | 360 | 336 | 295 | 226 |
| Employee cost | 82.59 | 65.10 | 58.55 | 58.00 | 62.97 | 58.22 | 50.03 |
| EBITDA | 101 | 111 | 20.47 | (10.28) | 62.36 | 82.69 | 66.19 |
| EBITDA margin | +19.2% | +23.5% | +6.1% | -2.9% | +15.7% | +21.9% | +22.7% |
| Depreciation | 21.70 | 24.22 | 24.72 | 28.25 | 25.56 | 20.31 | 15.00 |
| Interest | 12.66 | 14.89 | 17.43 | 21.37 | 17.98 | 19.00 | 20.09 |
| Profit before tax | 95.86 | 83.22 | (9.87) | (51.30) | 26.96 | 51.63 | 43.42 |
| Tax | 25.61 | 6.80 | 14.14 | 1.83 | 11.89 | 9.10 | (16.10) |
| Net profit | 62.91 | 81.06 | (16.63) | (23.95) | 15.47 | 45.64 | 57.78 |
| Net profit margin | +12.0% | +17.3% | -5.0% | -6.8% | +3.9% | +12.1% | +19.8% |
| EPS (₹) | 25.03 | 26.35 | (7.99) | (17.70) | 5.35 | 15.77 | 20.63 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 14.34 | 14.58 | 14.44 | 14.43 | 14.42 | 14.42 | 14.42 |
| Reserves & surplus | 392 | 348 | 274 | 301 | 358 | 346 | 295 |
| Shareholders' funds (net worth) | 406 | 363 | 289 | 315 | 372 | 361 | 309 |
| Minority interest | (5.67) | (4.16) | (3.70) | (2.75) | (0.68) | (0.30) | 0.01 |
| Secured loans | 109 | 109 | 132 | 217 | 236 | 229 | 220 |
| Unsecured loans | 4.44 | 5.54 | 6.50 | 2.68 | 3.04 | 2.86 | 3.69 |
| Total debt | 113 | 115 | 139 | 220 | 239 | 232 | 224 |
| Total liabilities | 541 | 498 | 465 | 562 | 622 | 598 | 539 |
| Assets | |||||||
| Gross block | 386 | 372 | 402 | 377 | 393 | 331 | 248 |
| Net block | 220 | 227 | 269 | 267 | 299 | 263 | 200 |
| Capital work in progress | 13.11 | 15.91 | 1.62 | 45.02 | 34.57 | 56.91 | 70.77 |
| Investments | 0.42 | 0.49 | 0.43 | 3.15 | 0.29 | 0.25 | 0.26 |
| Inventories | 153 | 124 | 87.38 | 130 | 159 | 162 | 129 |
| Sundry debtors | 112 | 95.23 | 69.83 | 41.65 | 87.09 | 68.01 | 69.77 |
| Cash & bank balances | 41.34 | 71.70 | 59.83 | 58.33 | 33.61 | 44.53 | 33.11 |
| Loans & advances | 82.55 | 44.66 | 24.71 | 20.13 | 33.85 | 34.80 | 52.54 |
| Total current assets | 388 | 335 | 242 | 250 | 314 | 310 | 284 |
| Total current liabilities | 107 | 116 | 82.57 | 74.77 | 84.59 | 89.29 | 75.05 |
| Net working capital | 282 | 219 | 159 | 175 | 229 | 220 | 209 |
| Total assets | 541 | 498 | 465 | 562 | 622 | 598 | 539 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 6.63 | 16.75 | 17.75 | (1.61) | 2.29 | (18.22) | 38.42 |
| Net cash from operating activities | 92.83 | 40.90 | 105 | 116 | 43.44 | 62.60 | 34.46 |
| Net cash from investing activities | (43.00) | (0.16) | (15.50) | (55.36) | (26.04) | (40.94) | (43.66) |
| Net cash from financing activities | (42.29) | (50.87) | (90.85) | (41.38) | (21.58) | (1.14) | (47.45) |
| Net change in cash | 7.55 | (10.12) | (1.00) | 19.37 | (4.17) | 20.52 | (56.65) |
| Closing cash | 41.34 | 71.70 | 59.83 | 58.33 | 33.61 | 44.53 | 33.11 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +11.9% | +39.9% | -4.1% | -12.2% | +5.6% | +29.3% | - |
| EBITDA growth | -8.6% | +439.9% | +299.1% | -116.5% | -24.6% | +24.9% | - |
| PBT growth | +15.2% | +9998.0% | +80.8% | - | -47.8% | +18.9% | -66.3% |
| Net income growth | -22.4% | +587.4% | +30.6% | -254.8% | -66.1% | -21.0% | - |
| Revenue CAGR (3Y) | +14.5% | +5.6% | -3.8% | +6.3% | -0.4% | +7.7% | +21.2% |
| EBITDA CAGR (3Y) | - | +21.0% | -37.2% | - | -25.3% | -3.9% | +76.9% |
| Profitability & leverage | |||||||
| Net income margin | +13.4% | +16.3% | -7.2% | -15.2% | +3.8% | +11.3% | +20.4% |
| Return on capital employed | +20.7% | +20.2% | +3.0% | -0.2% | +7.4% | +12.4% | +12.6% |
| Return on net worth | +18.3% | +23.5% | -5.8% | -7.6% | +4.1% | +12.7% | +21.3% |
| Debt / equity | 0.30 | 0.39 | 0.59 | 0.67 | 0.64 | 0.68 | 0.77 |
| Long-term debt / equity | 0.04 | 0.09 | 0.18 | 0.27 | 0.31 | 0.32 | 0.43 |
| Interest cover | 15.97 | 17.26 | -410.12 | -55.46 | 48.86 | 30.46 | 39.25 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.39 | 1.21 | 0.86 | 0.91 | 1.10 | 1.30 | 1.27 |
| Inventory turnover | 3.80 | 4.45 | 3.09 | 2.42 | 2.48 | 2.59 | 2.71 |
| Debtors turnover | 5.08 | 5.69 | 6.02 | 5.44 | 5.14 | 5.48 | 4.33 |
| EPS (₹) | 25.03 | 26.35 | (7.99) | (17.70) | 5.35 | 15.77 | 20.63 |
| Dividend per share (₹) | 3.75 | 2.50 | 1.25 | 1.25 | 1.25 | 2.50 | 5.00 |
| Book value per share (₹) | 141.68 | 124.33 | 100.04 | 109.27 | 129.00 | 125.00 | 107.27 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 112 | 110 | 114 | 107 | 119 | 122 | 146 | 89.54 |
| Revenue growth (YoY) | -6.0% | -10.0% | -21.9% | +19.6% | +63.7% | - | - | - |
| Other income | 4.90 | 15.17 | 3.43 | 5.53 | 8.84 | 3.88 | 2.22 | 2.95 |
| Total expenses | 88.86 | 88.04 | 92.88 | 84.15 | 96.49 | 89.36 | 96.12 | 74.05 |
| EBITDA | 22.98 | 21.84 | 21.36 | 22.97 | 22.53 | 32.68 | 50.13 | 15.49 |
| EBITDA margin | +20.5% | +19.9% | +18.7% | +21.4% | +18.9% | +26.8% | +34.3% | +17.3% |
| Depreciation | 5.19 | 5.08 | 5.17 | 5.13 | 5.55 | 5.60 | 5.82 | 5.89 |
| Interest | 2.54 | 2.77 | 3.03 | 2.59 | 3.11 | 2.99 | 4.09 | 3.69 |
| Profit before tax | 20.15 | 29.16 | 16.59 | 20.78 | 22.71 | 27.97 | 42.44 | 8.86 |
| Tax | 5.16 | 7.58 | 4.83 | 6.06 | 6.48 | (1.34) | 7.45 | 0.70 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 450 | 431 | 307 | 329 | 388 | 373 | 299 |
| Revenue growth | +4.6% | +40.2% | -6.6% | -15.2% | +4.1% | +24.6% | - |
| Other income | 30.87 | 11.68 | 8.15 | 8.46 | 7.53 | 6.62 | 12.31 |
| Total expenses | 359 | 330 | 279 | 350 | 311 | 278 | 229 |
| Employee cost | 74.14 | 60.10 | 53.93 | 53.81 | 59.36 | 57.50 | 50.03 |
| EBITDA | 91.67 | 101 | 28.33 | (20.61) | 76.82 | 94.73 | 70.45 |
| EBITDA margin | +20.4% | +23.4% | +9.2% | -6.3% | +19.8% | +25.4% | +23.5% |
| Depreciation | 20.94 | 23.17 | 23.70 | 24.49 | 23.67 | 19.03 | 14.94 |
| Interest | 12.38 | 14.84 | 17.40 | 21.35 | 18.11 | 19.10 | 20.27 |
| Profit before tax | 89.22 | 74.42 | (4.62) | (57.99) | 42.57 | 63.22 | 47.55 |
| Tax | 24.96 | 6.80 | 14.14 | (0.97) | 12.33 | 11.26 | (16.12) |
| Net profit | 55.21 | 71.71 | (7.75) | 3.07 | 30.26 | 52.09 | 61.77 |
| Net profit margin | +12.3% | +16.7% | -2.5% | +0.9% | +7.8% | +14.0% | +20.6% |
| EPS (₹) | 22.42 | 23.18 | (6.49) | (19.75) | 10.48 | 18.01 | 22.07 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 14.34 | 14.58 | 14.44 | 14.43 | 14.42 | 14.42 | 14.42 |
| Reserves & surplus | 408 | 365 | 300 | 322 | 382 | 356 | 298 |
| Shareholders' funds (net worth) | 423 | 380 | 314 | 336 | 396 | 370 | 313 |
| Secured loans | 109 | 109 | 132 | 217 | 236 | 229 | 220 |
| Unsecured loans | 4.44 | 5.54 | 6.50 | 2.68 | 4.79 | 4.65 | 5.56 |
| Total debt | 113 | 115 | 139 | 219 | 241 | 234 | 226 |
| Total liabilities | 563 | 519 | 494 | 585 | 649 | 610 | 544 |
| Assets | |||||||
| Gross block | 376 | 362 | 384 | 358 | 377 | 315 | 244 |
| Net block | 220 | 226 | 267 | 257 | 287 | 250 | 197 |
| Capital work in progress | 13.11 | 15.91 | 1.62 | 45.02 | 34.57 | 56.91 | 70.77 |
| Investments | 11.62 | 3.69 | 3.63 | 15.35 | 12.99 | 12.95 | 1.11 |
| Inventories | 131 | 94.48 | 78.61 | 110 | 130 | 133 | 114 |
| Sundry debtors | 137 | 120 | 77.13 | 67.41 | 118 | 96.12 | 77.44 |
| Cash & bank balances | 18.02 | 61.95 | 56.64 | 55.11 | 30.75 | 41.30 | 32.37 |
| Loans & advances | 73.62 | 43.87 | 25.85 | 18.27 | 37.10 | 37.75 | 59.10 |
| Total current assets | 360 | 321 | 238 | 251 | 315 | 308 | 282 |
| Total current liabilities | 89.22 | 103 | 70.20 | 78.67 | 64.12 | 72.80 | 65.96 |
| Net working capital | 270 | 218 | 168 | 172 | 251 | 235 | 216 |
| Total assets | 563 | 519 | 494 | 585 | 649 | 610 | 544 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | (3.12) | 13.56 | 14.54 | (4.49) | (0.94) | (18.96) | 38.02 |
| Net cash from operating activities | 82.63 | 33.83 | 105 | 124 | 50.41 | 62.96 | 29.83 |
| Net cash from investing activities | (46.00) | 0.41 | (15.15) | (63.47) | (32.46) | (43.61) | (39.19) |
| Net cash from financing activities | (42.15) | (50.91) | (90.86) | (41.25) | (21.76) | (1.32) | (47.63) |
| Net change in cash | (5.52) | (16.67) | (0.98) | 19.03 | (3.81) | 18.03 | (56.99) |
| Closing cash | 18.02 | 61.95 | 56.64 | 55.11 | 30.75 | 41.30 | 32.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +4.6% | +40.2% | -6.6% | -15.2% | +4.1% | +24.6% | - |
| EBITDA growth | -9.0% | +255.6% | +237.5% | -126.8% | -18.9% | +34.5% | - |
| PBT growth | +19.9% | +9998.0% | +92.0% | - | -32.7% | +33.0% | -60.7% |
| Net income growth | -23.0% | +1025.3% | -352.4% | -89.9% | -41.9% | -15.7% | - |
| Revenue CAGR (3Y) | +11.0% | +3.5% | -6.3% | +3.2% | -1.3% | +210.0% | +278.5% |
| EBITDA CAGR (3Y) | - | +9.5% | -33.1% | - | -18.5% | - | - |
| Profitability & leverage | |||||||
| Net income margin | +14.3% | +15.7% | -6.1% | -17.3% | +7.8% | +13.9% | +21.3% |
| Return on capital employed | +18.8% | +17.6% | +4.1% | +3.8% | +9.7% | +14.3% | +13.4% |
| Return on net worth | +16.0% | +19.5% | -2.4% | +0.8% | +7.9% | +15.2% | +22.7% |
| Debt / equity | 0.28 | 0.37 | 0.55 | 0.63 | 0.62 | 0.67 | 0.77 |
| Long-term debt / equity | 0.04 | 0.08 | 0.16 | 0.26 | 0.30 | 0.32 | 0.43 |
| Interest cover | 17.50 | 19.13 | 375.81 | -47.34 | 34.07 | 25.23 | 36.52 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.22 | 1.16 | 0.83 | 0.89 | 1.12 | 1.33 | 1.33 |
| Inventory turnover | 4.00 | 4.97 | 3.26 | 2.75 | 2.96 | 3.03 | 2.99 |
| Debtors turnover | 3.50 | 4.36 | 4.25 | 3.55 | 3.63 | 4.30 | 4.20 |
| EPS (₹) | 22.42 | 23.18 | (6.49) | (19.75) | 10.48 | 18.01 | 22.07 |
| Dividend per share (₹) | 3.75 | 2.50 | 1.25 | 1.25 | 1.25 | 2.50 | 5.00 |
| Book value per share (₹) | 147.47 | 130.26 | 108.83 | 116.45 | 137.26 | 128.42 | 108.36 |
To see the full year-wise statements and ratios of Fermenta Biotech Limited, buy the company report.
Board of directors of Fermenta Biotech Limited
Fermenta Biotech has 9 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Rajashri Santosh Kumar Ojha Also directs: Instapill Private Limited, Raaj Gprac Private Limited | Director | 01 Apr 2020 | 6 Years 6 Months | Current |
| Anupama Datla Desai | Whole-Time Director | 27 Sep 2019 | 7 Years 0 Months | Current |
| Satish Varma Azad Nadimpally | Whole-Time Director | 01 Jul 2003 | 23 Years 3 Months | Current |
| Prashant Prabhakar Nagre Also directs: Fermenta Environment Solutions Private Limited | Managing Director | 06 May 2021 | 5 Years 5 Months | Current |
| Krishna Vasantkumar Datla | Whole-Time Director | 09 May 2010 | 16 Years 5 Months | Current |
| Pramod Kasat Also directs: Advanced Enzyme Technologies Limited, Sai Silks (Kalamandir) Limited, Natural Capsules Limited and 5 more | Director | 30 May 2022 | 4 Years 4 Months | Current |
Auditor
Fermenta Biotech Limited is audited by S R B C & CO LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S R B C & CO LLP | FY 2023 | 324982E/E300003 |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 64.10%, foreign institutional investors hold 0.10%, domestic institutional investors hold 0.10% and retail and other public shareholders hold 35.70%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 64.10% | 64.10% | 64.10% | 64.10% |
| Public | 35.90% | 35.90% | 35.90% | 35.90% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 May 2023 | 100730973 | Yes Bank Limited | ₹16 Lakh | Open | |
| 30 Sep 2022 | 100620404 | Others | ₹68.43 Lakh | Open | |
| 21 Sep 2022 | 100611954 | Others | ₹66 Lakh | Open | |
| 07 Sep 2022 | 100608504 | Others | ₹27 Lakh | Open | |
| 24 Aug 2022 | 100608266 | Others | ₹17.92 Lakh | Open |
To see the full charge records of Fermenta Biotech Limited, buy the company report.
Total charge records: 72 View all charges
Legal cases
Fermenta Biotech Limited has 28 court cases on record: 15 filed by Fermenta Biotech, 13 filed against it. 2 cases are pending and 26 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 17 | 10 | 2 |
| High courts | 9 | 3 | 0 |
| NCLT | 2 | 0 | 0 |
Cases on record (5 of 28)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Jhajjar, Haryana | Court case (Rsuit) | Filed against the company by M/S Zeco Aircon Ltd Through Anand Kumar Gupta | Pending |
| Bombay High Court | Court case (CARAP) | Filed against the company by Hatim Glazing and Cladding Pvt.Ltd | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Civil suit | Filed against the company by Hatim Glazing and Cladding Pvt. Ltd. | Disposed |
| District court, Thane, Maharashtra | Civil suit | Filed by the company against Aha Air Hostess Academy Private Limited | Disposed |
| Bombay High Court | Court case (SJ) | Filed by the company against National Insurance Company Limited | Disposed |
To see the full case history of Fermenta Biotech Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Fermenta Biotech Limited has 13 MSME Form 1 returns on record between 2020 and 2024, listing 873 overdue payments to 148 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 148)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Supra Sciences Private Limited | |||
| an individual supplier | |||
| Vrata Tech Solutions Private Limited | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Fermenta Biotech Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Fermenta Biotech has 2 subsidiary companies and 1 associated company. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| G I Biotech Private Limited | U24230MH2004PTC148220 | |
| Aegean Properties Limited | U45200MH1995PLC084766 |
To see the full group structure of Fermenta Biotech Limited, buy the company report.
Employees & EPFO
Fermenta Biotech Limited has a workforce of 327 employees on its EPFO records as of Apr 09, 2024, across 4 active EPFO establishments.
GST
Fermenta Biotech has 14 GST registrations: 13 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACD0525E1Z9 | Maharashtra | Active | 01 Jul 2017 |
| 27AAACD0525E2Z8 | Maharashtra | Active | 02 Dec 2019 |
| 27AAACD0525E4Z6 | Maharashtra | Active | 07 Oct 2024 |
| 02AAACD0525E1ZL | Himachal Pradesh | Active | 10 Dec 2019 |
To see the full GST registrations and return filing status of Fermenta Biotech Limited, buy the company report.
Recent activity
Fermenta Biotech Limited has 29 board changes on record since 2001: 20 appointments and 9 cessations. The latest: Ramanand Mundkur was appointed as Director on 14 Nov 2024.
160 earlier events are in the company report.
News
Frequently asked questions
Fermenta Biotech is an active public limited company based in Thane, Maharashtra, India. The company works in api manufacturers, within the pharma industry. It was incorporated on 01 May 1951 (75+ years old) and is registered under CIN L99999MH1951PLC008485. Listed on BSE: 506414 and NSE: FERMENTA.
Fermenta Biotech reported revenue of ₹525.43 Cr for FY 2025-26 (up 11.9% YoY) based on consolidated financials.
Fermenta Biotech has 9 current directors:
- Prashant Prabhakar Nagre - Managing Director
- Anupama Datla Desai - Whole-Time Director
- Satish Varma Azad Nadimpally - Whole-Time Director
- Krishna Vasantkumar Datla - Whole-Time Director
- Rajashri Santosh Kumar Ojha - Director
- Pramod Kasat - Director
- Rajeshwari Datla - Director
- Ramanand Mundkur - Director
- Pradeep Manjunath Chandan - Director
The latest financial statements of Fermenta Biotech on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 12 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Fermenta Biotech is 27AAACD0525E1Z9, registered in Maharashtra. The company has 14 GST registrations in all, of which 13 are active and 1 is cancelled or inactive. Other active GSTINs include 27AAACD0525E2Z8 (Maharashtra), 27AAACD0525E4Z6 (Maharashtra), 02AAACD0525E1ZL (Himachal Pradesh).
The CIN (Corporate Identification Number) of Fermenta Biotech is L99999MH1951PLC008485. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Fermenta Biotech is a listed company as per MCA records. Its shares are listed on both BSE (code: 506414) and NSE (symbol: FERMENTA).
Fermenta Biotech has 28 court cases on record: 15 filed by the company and 13 filed against it. 2 are pending. Most are in the district courts.
Fermenta Biotech was incorporated on 01 May 1951, making it 75+ years old. It is registered with the Registrar of Companies, Mumbai.
Ramanand Mundkur was appointed as Director on 14 Nov 2024. Varadvinayak Vijay Khambete was appointed as Company Secretary on 30 Jul 2024. Srikant Nath Sharma ceased to be Company Secretary on 23 Jul 2024. Fermenta Biotech has 29 board changes on record in total.
Fermenta Biotech has 13 MSME Form 1 returns on record between 2020 and 2024, listing 873 overdue payments to 148 micro and small suppliers. The latest return was filed on 01 May 2024.